Navigation Links
Zafgen Secures $45 Million in Series E Financing
Date:12/4/2013

CAMBRIDGE, Mass., Dec. 4, 2013 /PRNewswire/ -- Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced it has secured $45 million in a Series E equity financing.  New investors include RA Capital Management, Brookside Capital, Venrock, Alta Partners, an undisclosed blue chip investor, and a private investor.  Proceeds from the financing will be used to support the continued development of beloranib, the Company's obesity therapeutic.  Zafgen recently reported Phase 2 study results, which demonstrated that beloranib treatment led to significant weight loss and improvements in multiple cardiometabolic risk factors in 147 obese subjects.

"We are excited to add this group of new investors to our syndicate and to obtain continued investment from Alta Partners who led our Series D round last year, as we continue to advance our clinical testing for beloranib in severe obesity and related orphan indications," said Thomas Hughes, Ph.D., president and chief executive officer, Zafgen, Inc.  "With their support, we look forward to building on our recent Phase 2 results and expanding the beloranib program to help patients who suffer from these serious diseases."  

"Zafgen has continued to attract high quality investors to its syndicate in support of beloranib," said Peter Barrett of Atlas Venture and Chairman of the Board of Zafgen.  "Zafgen's newest investors support some of the most innovative companies and their investment demonstrates confidence in beloranib as a unique pharmacotherapeutic with the potential to address the unmet needs of severely obese patients."

About Zafgen, Inc.

Zafgen is an innovative company dedicated to addressing the unmet need of severely obese patients and related orphan indications by bringing beloranib, a first-in-class no
'/>"/>

SOURCE Zafgen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Zafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013
2. Zafgen Secures $21 Million in Series D Financing
3. Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
4. Collaborative Medical Technology Corporation Secures Investments from Two Prominent Medical Specialists
5. Calithera Biosciences Secures $35 Million in Series D Financing
6. Harrisvaccines, Inc. Secures Exclusive Rights From AlphaVax, Inc. to Develop RNA Particle Vaccines for All Diseases in Companion Animals
7. Arvinas Secures $18.25 Million to Advance Clinical Programs Focused on Protein Degradation
8. Predilytics Secures Additional Funding and Expands Board of Directors
9. VisionCare Ophthalmic Technologies Secures Up To $15MM To Accelerate Growth Of Its Novel Treatment For Age-Related Macular Degeneration
10. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
11. Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)...  Boston Scientific has released the primary endpoint ... Failure (NECTAR-HF) clinical trial, the first and only ... (VNS) for the treatment of heart failure patients.  ... Cardiology and Director of the Clinical Investigation Center ... de la Recherche Medicale presented the results at ...
(Date:8/30/2014)... Mass. , Aug. 30, 2014   Royal ... of Affiniti, a new ultrasound system designed ... the demands of increasing patient volumes and cost pressures. ... Congress 2014 in Barcelona ... departments facing more patients with fewer resources deliver high ...
(Date:8/29/2014)... /PRNewswire-iReach/ -- Market Research Report on Global and ... professional and in-depth market survey on Global ... report firstly reviews the basic information of X-Ray ... technology. The report then explores global and China,s ... product specification, capacity, Production value, and market share ...
Breaking Medicine Technology:Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 2Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 3Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 4Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5
(Date:8/31/2014)... (PRWEB) August 31, 2014 Green ... harmful disc brake dust at the source while ... Problem: Millions of vehicles globally emit brake dust/debris ... in the friction materials (disc brake pads) are ... nations’ water systems. For example, copper impairs and ...
(Date:8/31/2014)... Priya Khan, Director of Research & Development at ... weight-loss supplements saying, “Consumers are understandably frustrated with ... propagated by unscrupulous companies about weight-loss products.” Even ... the subject. , NutriGold’s mission is to educate ... and to provide them with guidelines for choosing ...
(Date:8/31/2014)... August 31, 2014 To make it ... brand they can trust, NutriGold is shipping complimentary samples ... form has been set up to make taking advantage ... , According to Priya Khan, Director of Research and ... purchase one of our products, they are entrusting us ...
(Date:8/31/2014)... 2014 “Prohibition is our history,” ... our future: the present ~ that’s political.” , ... , new on the Bryan William Brickner Blog, ... system (CS) modulation and homeostasis - including one ... use. The Publius CS update includes: heteromerization ...
(Date:8/31/2014)... Top10BestSEOHosting.com has recently compared many professional web ... ), Bluehost and GoDaddy are the best hosting ... Top10BestSEOHosting.com says, “These companies have outperformed other competitors ... so that we call them the Best VPS ... get the best web hosting to enjoy the ...
Breaking Medicine News(10 mins):Health News:CBPModular Technology with Global Patent Coverage Solves Vehicle Wheel Brake Dust Problem 2Health News:New Reasons to Verify Label Claims on Weight-loss Products Before Buying 2Health News:New Reasons to Verify Label Claims on Weight-loss Products Before Buying 3Health News:Whole-food Supplement Samples Now Offered by NutriGold 2Health News:Whole-food Supplement Samples Now Offered by NutriGold 3Health News:Homeostasis: Publius’ Alcohol Political Cannabinoid Science ~ New on the Bryan William Brickner Blog 2Health News:Top10BestSEOHosting.com Announces The Best Hosting Suppliers In 2014: iPage, Bluehost and GoDaddy 2
... events , WEDNESDAY, May 5 (HealthDay News) -- A ... significantly cuts down on hospital drug errors, researchers from ... "We had the opportunity to design and implement a ... the hospital gets the right medication at the right ...
... those mental illnesses are still common, especially among women, survey ... report finds that older people have lower rates of mental ... the conditions remain common, especially in women. , Researchers led ... San Francisco analyzed a survey of 2,575 people aged 55 ...
... it may not help older men and women with sexual problems ... partner report greater happiness and those who talked with friends ... Journal of Gerontology: Social Sciences , shows that the way ... later years varies greatly and that there is not one solution ...
... ... Healthy CHOICES Act, and just days after the release of America’s first-ever ... and leaders from the fitness industry are gathering on Capitol Hill as ... will meet with Members of Congress to share their vision for a ...
... ... with online resources dedicated to the technical requirements associated with large format touch screens. ... particular makes this need an immediate one. See how they answered the call... ... (PRWEB) May 5, ...
... Research Institute (CRI) is participating in an international study ... and chronic lymphocytic leukemia. "This study is important ... to treat patients with leukemia or lymphoma," said Arthur ... Research Institute, and principal investigator for the Temple portion ...
Cached Medicine News:Health News:Bar Codes Cut Down on Hospital Medication Errors 2Health News:Bar Codes Cut Down on Hospital Medication Errors 3Health News:Friendship and confiding in spouse eases stress over sexual issues in older men 2Health News:Friendship and confiding in spouse eases stress over sexual issues in older men 3Health News:Fitness Industry Gathers on Capitol Hill Hours After Healthy CHOICES Act is Introduced, Urging Congress to Pass Anti-Obesity, Exercise Promotion Legislation 2Health News:Fitness Industry Gathers on Capitol Hill Hours After Healthy CHOICES Act is Introduced, Urging Congress to Pass Anti-Obesity, Exercise Promotion Legislation 3Health News:Fitness Industry Gathers on Capitol Hill Hours After Healthy CHOICES Act is Introduced, Urging Congress to Pass Anti-Obesity, Exercise Promotion Legislation 4Health News:Fitness Industry Gathers on Capitol Hill Hours After Healthy CHOICES Act is Introduced, Urging Congress to Pass Anti-Obesity, Exercise Promotion Legislation 5Health News:Horizon Display Demonstrates their Dedication to After-Sales Support with Enhanced Online Resources 2Health News:Horizon Display Demonstrates their Dedication to After-Sales Support with Enhanced Online Resources 3Health News:Scott & White Healthcare clinical trials target lymphoma, leukemia 2
A One Piece Support Garment - any length or size...
Body Suit w/Bra torso...
Male Compression Vest Binder...
Ideal for breast compression with adjustable hook and eye closure....
Medicine Products: